• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Tharimmune, Inc. Closes $545 Million Private Placement to Establish Canton Coin Treasury Strategy

    11/6/25 4:16:00 PM ET
    $THAR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $THAR alert in real time by email

    Led by DRW and Liberty City Ventures, Transaction Cements Tharimmune as First Public Company to Deliver Canton-Aligned DAT Strategy

    Net Proceeds Support Acquisition of Canton Coin and Active Network Participation via Validator Infrastructure and Application Development

    NEW YORK, Nov. 6, 2025 /PRNewswire/ -- Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a publicly traded company that will leverage the Canton Coin ("CC") to support the Canton Network's ability to digitize traditional financial markets, today announced the successful close of its previously announced private placement for the purchase and sale of shares of common stock (or par-value pre-funded warrants in lieu thereof) at a price of $3.075 per share, resulting in aggregate gross proceeds of approximately $545 million, before deducting placement agent fees and other offering expenses (the "Offering").

    Tharimmune intends to use the net proceeds to acquire CC, the utility token supporting interoperability and settlement across the Canton Network, and to support the Company's plans to operate as a Super Validator and run additional Validators on the Canton Network. Net proceeds will also be used for working capital and general corporate purposes.

    Led by DRW and Liberty City Ventures, notable investors also included ARK Invest, Bitwave, Broadridge, Clear Street, Copper, Digital Asset, Fairmint Inc., Feynman Point Asset Management, Five North, IntellectEU, Kaiko, Kenetic, Kraken, LendOS, Lukka, MPCH, Nima Capital, Obsidian Software, Polychain Capital, Proof Group, SBI Group, The Tie, Tradeweb Markets, and 7RIDGE. The Canton Foundation, the governing body overseeing the Canton Network, also participated, making Tharimmune the first and only publicly traded company supported by the Canton Foundation.

    Through active participation in the Canton Network – a privacy-enabled, secure blockchain already hosting trillions in assets on chain – Tharimmune plans to execute a differentiated digital asset treasury ("DAT") strategy. Unlike other DAT strategies, Tharimmune has a diversified approach, and intends to drive value not only by acquiring CC, but also by applying to operate as a Super Validator and investing in applications built on the Canton Network that accelerate institutional utility and adoption across capital markets.

    To move this strategy forward, Mark Wendland, former Partner and Chief Operating Officer at DRW, has been appointed as Chief Executive Officer of the Company overseeing the DAT strategy, with Mark Toomey, former Managing Director and Head of Business Development at Liberty City Ventures, appointed as President of the Company. The existing management team will continue to oversee its clinical-stage biotechnology operations. Mark Wendland will also join the Board of Directors of the Company.  

    "Closing this financing represents an important step in bringing the differentiated value of the Canton Network to public markets," said Mr. Wendland. "Our treasury strategy is built around the conviction that the future financial system will be shaped by those delivering the level of programmability, privacy, and interoperability that we see today in the Canton Network. Canton sits at the center of institutional blockchain adoption, and we are aligning our platform to support both its long-term growth and the creation of durable value for shareholders."

    Mr. Toomey added, "We are entering a new era where public markets will benefit from the transparency, efficiency, and programmability enabled by the Canton Network. At Tharimmune, we are committed to setting the standard for how companies can engage with this technology in a responsible and value-accretive manner by supporting the development of real-world applications and accelerating the future of institutional finance."

    The Canton Network is purpose-built to power the next generation of institutional financial infrastructure, enabling privacy-preserving, interoperable applications across global capital markets. With participation from world-class financial institutions including Broadridge, Goldman Sachs, Tradeweb Markets, DTCC, DRW, and BNP Paribas, Canton provides the regulatory alignment, scalability, and settlement guarantees required by highly regulated market participants.

    According to Copper Research, the Canton Network processed more than 500,000 daily transactions as of September 30, 2025, confirming its ability to support real-world financial workloads and advanced workflows. This growth reflects increasing demand for tokenization frameworks align with institutional requirements for comprehensive blockchain adoption.

    Advisors

    Clear Street acted as sole placement agent and a financial advisor in connection with the Offering.

    President Street Global served as a financial advisor in connection with the Offering.

    Lucosky Brookman LLP and Sheppard Mullin Richter & Hampton LLP served as counsel to Tharimmune.

    Paul Hastings LLP served as counsel to Clear Street.

    Reed Smith LLP served as counsel to DRW.

    Securities Disclaimers:

    The information provided in this press release is intended for informational purposes only and does not constitute investment advice, endorsement, analysis, or recommendations with respect to any financial instruments, investments, or issuers. Investment in cryptocurrency involves substantial risk, including the risk of complete loss. This press release does not take into account the investment objectives, financial situation, or specific needs of any particular person and each individual is urged to consult their legal and financial advisors before making any investment decisions.

    The offer and sale of the securities in the Offering, including the shares of common stock underlying the pre-funded warrants, was made to institutional accredited investors in a transaction not involving a public offering pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended (the "Securities Act") and have not been registered under the Securities Act or applicable state securities laws. Accordingly, the securities issued in the Offering and shares of common stock underlying the pre-funded warrants may not be offered or sold in the United States except pursuant to an effective registration statement with the Securities and Exchange Commission ("SEC") or an applicable exemption from the registration requirements of the Securities Act and such other applicable state securities laws.

    This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

    The private placement was conducted in accordance with applicable Nasdaq rules and was priced to satisfy the "Minimum Price" requirement (as defined in the Nasdaq rules).

    About Tharimmune

    Tharimmune, Inc. (NASDAQ:THAR) is the first publicly traded company to leverage CC and support the Canton Network to advance institutional blockchain adoption and the digitization of financial markets. In addition to driving value through activities on the Canton Network, Tharimmune also operates clinical-stage biotech research and development. For more information, visit: www.tharimmune.com.

    Cautionary Note Regarding Forward-Looking Statements

    This press release contains statements that constitute "forward-looking statements" within the meaning of the U.S. federal securities laws. Forward-looking statements are statements other than historical facts and include, without limitation, statements regarding the potential for and amount of additional cash proceeds from warrant exercises, the anticipated use of proceeds from the announced Offering, future stockholder approvals, future announcements and priorities, expectations regarding management, corporate governance, market position, business strategies, future financial and operating performance, and other projections or statements of plans and objectives.

    These forward-looking statements are based on current expectations, estimates, assumptions, and projections, and involve known and unknown risks, uncertainties, and other factors—many of which are beyond the Company's control—that may cause actual results, performance, or achievements to differ materially from those expressed or implied by such statements. Important factors that may affect actual results include, among others, the Company's ability to execute its growth strategy; its ability to raise and deploy capital effectively; developments in technology and the competitive landscape; the market performance of CC; and other risks and uncertainties described under "Risk Factors" in the Company's Annual Report on Form 10-K filed with the SEC on March 26, 2025, and in other subsequent filings with the SEC. These filings are available at www.sec.gov. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

    Contacts

    Media:

    Gasthalter & Co.

    (212) 257-4170

    [email protected]

    Investors: 

    [email protected]

    Twitter/X: @TharimmuneInc

    Website: https://tharimmune.com/

    Cision View original content:https://www.prnewswire.com/news-releases/tharimmune-inc-closes-545-million-private-placement-to-establish-canton-coin-treasury-strategy-302607840.html

    SOURCE Tharimmune, Inc.

    Get the next $THAR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $THAR

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $THAR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Wendland Mark Paul

    3 - Tharimmune, Inc. (0001861657) (Issuer)

    11/14/25 2:20:50 PM ET
    $THAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Toomey Mark Christopher

    3 - Tharimmune, Inc. (0001861657) (Issuer)

    11/14/25 2:18:38 PM ET
    $THAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Stetz Gary S.

    4 - Tharimmune, Inc. (0001861657) (Issuer)

    11/5/25 8:57:16 PM ET
    $THAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $THAR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Tharimmune, Inc. Appoints Jacob Asbury as Chief Financial Officer to Advance Canton Coin Treasury Strategy

    Former Clear Street Group CFO Strengthens Leadership Team Alongside Industry Veterans Mark Wendland and Mark Toomey Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), the first publicly traded company to leverage Canton Coin ("CC") to support the Canton Network's ability to digitize traditional financial markets, today announced the appointment of seasoned financial executive Jacob Asbury as Chief Financial Officer, effective immediately. In this role, he will oversee all financial strategy and operations, including capital planning, treasury management, financial reporting, and the continued expansion of Tharimmune's CC treasury infrastructure. Mr. Asbury brings nearly two d

    12/12/25 8:15:00 AM ET
    $THAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tharimmune Receives Positive FDA Feedback for TH104 Prophylaxis Program Against Respiratory Depression from Fentanyl and Ultrapotent Opioids

    RED BANK, N.J., Nov. 13, 2025 /PRNewswire/ -- Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a digital asset treasury company with a clinical-stage biotechnology function, today announced an update from the biotechnology side of the business. Its lead clinical asset, TH104 (nalmefene buccal film), received positive feedback from the U.S. Food and Drug Administration (FDA) on the Company's submitted simulation modeling plan. Tharimmune announced earlier this month its plans to develop a digital asset treasury strategy that leverages the Canton Coin to support the Canton Network's ability to digitize traditional financial markets. In a formal Type D meeting with the FDA, Thar

    11/13/25 8:05:00 AM ET
    $THAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tharimmune, Inc. Closes $545 Million Private Placement to Establish Canton Coin Treasury Strategy

    Led by DRW and Liberty City Ventures, Transaction Cements Tharimmune as First Public Company to Deliver Canton-Aligned DAT Strategy Net Proceeds Support Acquisition of Canton Coin and Active Network Participation via Validator Infrastructure and Application Development NEW YORK, Nov. 6, 2025 /PRNewswire/ -- Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a publicly traded company that will leverage the Canton Coin ("CC") to support the Canton Network's ability to digitize traditional financial markets, today announced the successful close of its previously announced private placement for the purchase and sale of shares of common stock (or par-value pre-funded warrants in lieu

    11/6/25 4:16:00 PM ET
    $THAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $THAR
    SEC Filings

    View All

    Tharimmune Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Tharimmune, Inc. (0001861657) (Filer)

    12/12/25 8:45:36 AM ET
    $THAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-3 filed by Tharimmune Inc.

    S-3 - Tharimmune, Inc. (0001861657) (Filer)

    12/5/25 4:52:48 PM ET
    $THAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B3 filed by Tharimmune Inc.

    424B3 - Tharimmune, Inc. (0001861657) (Filer)

    12/5/25 4:13:14 PM ET
    $THAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $THAR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Executive Chairman Gravitas Capital Lp bought $500,000 worth of shares (337,838 units at $1.48), increasing direct ownership by 86% to 732,424 units (SEC Form 4)

    4 - Tharimmune, Inc. (0001861657) (Issuer)

    6/23/25 9:29:23 PM ET
    $THAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Parikh Sanam bought $1,450 worth of shares (1,000 units at $1.45), increasing direct ownership by 130% to 1,770 units (SEC Form 4)

    4 - Tharimmune, Inc. (0001861657) (Issuer)

    6/23/25 7:34:56 PM ET
    $THAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Appajosyula Sireesh bought $90,973 worth of shares (61,496 units at $1.48), increasing direct ownership by 1,824% to 64,868 units (SEC Form 4)

    4 - Tharimmune, Inc. (0001861657) (Issuer)

    6/23/25 7:31:11 PM ET
    $THAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $THAR
    Leadership Updates

    Live Leadership Updates

    View All

    Tharimmune, Inc. Appoints Jacob Asbury as Chief Financial Officer to Advance Canton Coin Treasury Strategy

    Former Clear Street Group CFO Strengthens Leadership Team Alongside Industry Veterans Mark Wendland and Mark Toomey Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), the first publicly traded company to leverage Canton Coin ("CC") to support the Canton Network's ability to digitize traditional financial markets, today announced the appointment of seasoned financial executive Jacob Asbury as Chief Financial Officer, effective immediately. In this role, he will oversee all financial strategy and operations, including capital planning, treasury management, financial reporting, and the continued expansion of Tharimmune's CC treasury infrastructure. Mr. Asbury brings nearly two d

    12/12/25 8:15:00 AM ET
    $THAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tharimmune Announces Phase 2 Study Plan for TH104 in Patients With Moderate-to-Severe Pruritus Associated With Primary Biliary Cholangitis and Provides a Business Update

    BRIDGEWATER, NJ / ACCESSWIRE / December 16, 2024 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company committed to pioneering therapies in immunology and inflammation, today announced plans for initiating a Phase 2 study evaluating TH104 in patients suffering from moderate-to-severe pruritus (severe itching) associated with primary biliary cholangitis (PBC), a rare and chronic liver disease, and also provided a corporate update. The launch of this clinical trial, expected in 2025, follows favorable results from Tharimmune's Phase 1 study with TH104, recent regulatory feedback from the European Medicines Agency (EMA) and the U.S. Food and Dr

    12/16/24 8:00:00 AM ET
    $THAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tharimmune Appoints Prof. David Jones of Newcastle University to its Scientific Advisory Board

    BRIDGEWATER, NJ / ACCESSWIRE / July 22, 2024 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, today announced the appointment of David Jones, Professor of Liver Immunology at Newcastle University in England, to its Scientific Advisory Board (SAB).Prof. Jones has earned an international reputation for his work in autoimmune liver disease. He leads the UK-PBC research consortium (MRC Stratified Medicine), which has the world's largest cohort of fully phenotyped primary biliary cholangitis/cirrhosis (PBC) patients. His areas of expertise include stratified the

    7/22/24 8:30:00 AM ET
    $THAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $THAR
    Financials

    Live finance-specific insights

    View All

    Tharimmune Acquires Global License and Partners With Intract Pharma to Develop an Oral Formulation of Infliximab

    BRIDGEWATER, NJ and LONDON, UK / ACCESSWIRE / September 16, 2024 /Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, announced today that it has entered into a definitive agreement with Intract Pharma to exclusively license INT-023/TH023, an oral anti-tumor necrosis factor-alpha (TNF-α) monoclonal antibody, infliximab. This strategic partnership aims to expand Tharimmune's therapeutic pipeline and reinforce its commitment to pioneering novel treatments for autoimmune diseases.Under the terms of the agreement, Tharimmune licensed global development and commercia

    9/16/24 7:00:00 AM ET
    $THAR
    Biotechnology: Pharmaceutical Preparations
    Health Care